Autotitrating Non-invasive Ventilation (NIV) Versus Standard NIV; a Randomised Crossover Trial in Patients With Newly Diagnosed Hypoventilation
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Nocturnal Hypoventilation
- Sponsor
- ResMed
- Enrollment
- 23
- Locations
- 1
- Primary Endpoint
- Overnight Mean Oxygen Saturation
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The aim of the study is to compare the efficacy and tolerance of autotitrating non-invasive ventilation (NIV) versus standard NIV in patients with newly diagnosed nocturnal hypoventilation who have never experienced nocturnal, home NIV.
Detailed Description
The aim of the study is to compare the effect of two types of noninvasive ventilator (a small machine that assists breathing) in patients newly diagnosed with nocturnal hypoventilation who are inexperienced in the use of noninvasive ventilation (NIV). NIV is standard therapy for patients with nocturnal hypoventilation. The most common type of NIV is bilevel pressure support which assists patient breathing by delivering different levels of air pressure during inspiration and expiration via a mask covering the nose or nose and mouth. Standard bilevel NIV (VPAP™) has been further developed to create a new automatically adjusting NIV (AutoVPAP™). Automatically adjusting NIV varies the inspiratory air pressure according to the airflow rates generated by the patient. This may improve patient comfort, hours of NIV use and recovery time. Patients over the age of 18 referred to, or under follow up at, the Royal Brompton Hospital who require domiciliary NIV but are inexperienced with use of NIV will be considered for entry into this randomised crossover study. If eligible for inclusion and willing to take part patients will be setup on automatically adjusting NIV or standard NIV, assigned in random order. At the end of one month the patient will be swapped to the alternative NIV for a further one month of domiciliary NIV treatment. At the end of each one month treatment period the patient will undergo overnight polysomnography, transcutaneous CO2 monitoring and 24 hour Holter monitoring.
Investigators
Eligibility Criteria
Inclusion Criteria
- •new clinical diagnosis of nocturnal hypoventilation
- •requirement for long-term domiciliary non-invasive ventilation
- •no previous experience with domiciliary non-invasive ventilation
Exclusion Criteria
- •uncontrolled cardiac failure
- •acute exacerbation of respiratory failure
- •daytime resting PaO2 \< 7.5kPa
- •moderate or severe bulbar weakness
- •inability to understand rationale and/or consent form for study
Outcomes
Primary Outcomes
Overnight Mean Oxygen Saturation
Time Frame: 4 weeks
Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.
Secondary Outcomes
- Overnight Mean Transcutaneous Carbon Dioxide(4 weeks)
- Sleep Quality: Arousal Index(4 weeks)
- Oxygen Desaturation Index (>4%)(4 weeks)
- Overnight Peak Transcutaneous Carbon Dioxide(4 weeks)